Last reviewed · How we verify
Naftidan (NAFIVERINE)
Naftidan (generic name: NAFIVERINE) is a nafiverine drug. It is currently in Phase 2 development.
Nafiverine is thought to work by interacting with a specific molecular target to produce a therapeutic effect.
Nafiverine is a small molecule drug in the nafiverine class, developed by an unknown original developer and currently owned by an unknown entity. Its target and exact mechanism of action are not specified. Nafiverine is not FDA-approved for any indications, and its commercial status, half-life, bioavailability, generic manufacturers, and off-patent status are unknown. As a result, there is limited information available on its safety profile and clinical use. Further research is needed to determine its potential therapeutic applications and risks.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | NAFIVERINE |
|---|---|
| Drug class | nafiverine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have locks on them, and nafiverine is a key that fits into one of those locks. When it binds to the lock, it triggers a series of events that ultimately lead to a desired outcome, such as relieving a particular symptom or condition. This is a simplified explanation of how nafiverine is believed to work at a molecular level.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naftidan CI brief — competitive landscape report
- Naftidan updates RSS · CI watch RSS
Frequently asked questions about Naftidan
What is Naftidan?
How does Naftidan work?
What is the generic name of Naftidan?
What drug class is Naftidan in?
What development phase is Naftidan in?
Related
- Drug class: All nafiverine drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing